Actinium to present first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer at ESMO 2026

Actinium Pharmaceuticals will present a first-in-human Phase 1 study of ATNM-400, a HER3-targeted, non-PSMA radiotherapy, in metastatic castration-resistant prostate cancer at the ESMO Congress 2026.

Detected & updated continuously · Source: Nebula